Literature DB >> 16453109

[Expression of angiotensin I converting enzyme in pulmonary hypertension].

A M Müller1, M Maas, U Kozianka, F E Franke.   

Abstract

We studied angiotensin I converting enzyme (ACE) expression in lung tissue from patients with different forms of pulmonary hypertension (PH) in comparison with that from morphologically normal lung specimens. ACE antigen expression was analysed by immunohistochemistry in morphologically normal lung tissue from 33 patients (19 males, 32-77 years; 14 females, 34-93 years) and compared to that in specimens from 94 patients (67 males, 30-97 years; 27 females: 27-90 years) with different clinically proven forms of PH (according to Venedig classification). Type specific vessel expression pattern as described for normal lung tissue was generally intensified in arteries, arterioles and capillaries of the lung specimens with PH. Specimens with PH due to left heart disease and chronic obstructive pulmonary disease (COPD) showed only very weak or no augmented arterial ACE expression, while PH due to collagenoses or interstitial lung disease showed significantly higher ACE expression. In human PH there is--comparable to animal models--a raised ACE expression in pulmonary lung vessels, with differences between the various forms of PH. These differences in ACE expression may be relevant for subtly differentiated therapeutic anti-ACE therapy regimes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16453109     DOI: 10.1007/s00292-006-0820-7

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  34 in total

Review 1.  Endothelial cell heterogeneity.

Authors:  William C Aird
Journal:  Crit Care Med       Date:  2003-04       Impact factor: 7.598

2.  Short- and long-term hemodynamic effects of captopril in patients with pulmonary hypertension and selected connective tissue disease.

Authors:  M A Alpert; T A Pressly; V Mukerji; C R Lambert; B Mukerji
Journal:  Chest       Date:  1992-11       Impact factor: 9.410

3.  [Pulmonary hypertension in chronic myeloproliferative disorders].

Authors:  B M Einsfelder; K-M Müller
Journal:  Pathologe       Date:  2005-05       Impact factor: 1.011

4.  Impact of angiotensin converting enzyme inhibition on post-coronary artery bypass interleukin 6 release.

Authors:  D J Brull; J Sanders; A Rumley; G D Lowe; S E Humphries; H E Montgomery
Journal:  Heart       Date:  2002-03       Impact factor: 5.994

5.  The DD genotype of the angiotensin converting enzyme gene is negatively associated with right ventricular hypertrophy in male patients with chronic obstructive pulmonary disease.

Authors:  R J van Suylen; E F Wouters; H J Pennings; E C Cheriex; P E van Pol; A W Ambergen; A M Vermelis; M J Daemen
Journal:  Am J Respir Crit Care Med       Date:  1999-06       Impact factor: 21.405

6.  Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor.

Authors:  Carl Atkinson; Susan Stewart; Paul D Upton; Rajiv Machado; Jennifer R Thomson; Richard C Trembath; Nicholas W Morrell
Journal:  Circulation       Date:  2002-04-09       Impact factor: 29.690

7.  Long-term inhibition of nitric oxide synthesis increases arterial thrombogenecity in rat carotid artery.

Authors:  Mayuko Kubo-Inoue; Kensuke Egashira; Makoto Usui; Masao Takemoto; Kisho Ohtani; Makoto Katoh; Hiroaki Shimokawa; Akira Takeshita
Journal:  Am J Physiol Heart Circ Physiol       Date:  2002-04       Impact factor: 4.733

Review 8.  The pulmonary renin-angiotensin system.

Authors:  Richard P Marshall
Journal:  Curr Pharm Des       Date:  2003       Impact factor: 3.116

9.  Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells.

Authors:  A A Geisterfer; M J Peach; G K Owens
Journal:  Circ Res       Date:  1988-04       Impact factor: 17.367

10.  Angiotensin converting enzyme expression is increased in small pulmonary arteries of rats with hypoxia-induced pulmonary hypertension.

Authors:  N W Morrell; E N Atochina; K G Morris; S M Danilov; K R Stenmark
Journal:  J Clin Invest       Date:  1995-10       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.